经皮冠状动脉介入治疗患者接受1个月双联抗血小板治疗后转为氯吡格雷单药治疗与12个月双联抗血小板治疗对心血管及出血事件的影响:STOPDAPT-2随机临床试验
STOPDAPT-2多中心开放标签随机试验纳入日本90家医院3045例接受药物洗脱支架PCI的患者,比较1个月DAPT后氯吡格雷单药与12个月阿司匹林联合氯吡格雷DAPT。1个月DAPT组主要终点(心血管死亡、心肌梗死、缺血性或出血性卒中、明确支架血栓或大/小出血)发生率为2.36%,12个月DAPT组为3.70%,达到非劣效和优效;主要次要出血终点1个月DAPT组0.41%低于12个月DAPT组1.54%。
要点
- 1个月DAPT后氯吡格雷单药的主要复合终点发生率2.36%,低于12个月DAPT的3.70%(HR 0.64,95%CI 0.42-0.98)。
- 主要次要心血管终点1个月DAPT组1.96% vs 12个月DAPT组2.51%(HR 0.79,95%CI 0.49-1.29),达到非劣效但未达优效。
- 主要次要出血终点1个月DAPT组0.41% vs 12个月DAPT组1.54%(HR 0.26,95%CI 0.11-0.64;优效性P=0.004)。
核心结论
- 在接受PCI的患者中,与12个月阿司匹林联合氯吡格雷DAPT相比,1个月DAPT后氯吡格雷单药治疗的心血管与出血复合终点发生率显著更低,同时达到非劣效和优效标准。
- 这些发现提示较短的DAPT疗程可能带来获益,但鉴于研究局限性,需在其他人群中进行进一步研究。
研究设计与样本
- 多中心、开放标签、随机临床试验,于2015年12月至2017年12月在日本90家医院纳入3045例接受PCI的患者,最终1年临床随访于2019年1月完成。
- 患者随机分为1个月DAPT后氯吡格雷单药治疗组(n=1523)或12个月阿司匹林联合氯吡格雷DAPT组(n=1522)。
- 随机化3045例患者中36例撤回知情同意,剩余3009例中2974例(99%)完成试验。
主要发现
- 主要终点(12个月时心血管死亡、心肌梗死、缺血性或出血性卒中、明确支架血栓或大/小出血的复合终点)1个月DAPT组发生率为2.36%,12个月DAPT组为3.70%(绝对差异-1.34%[95%CI,-2.57%至-0.11%];HR 0.64[95%CI,0.42-0.98]),非劣效性P<.001,优效性P=.04。
- 主要次要心血管终点(心血管死亡、心肌梗死、缺血性或出血性卒中或明确支架血栓的复合终点)1个月DAPT组发生率为1.96%,12个月DAPT组为2.51%(绝对差异-0.55%[95%CI,-1.62%至0.52%];HR 0.79[95%CI,0.49-1.29]),非劣效性P=.005,优效性P=.34。
- 主要次要出血终点(大或小出血)1个月DAPT组发生率为0.41%,12个月DAPT组为1.54%(绝对差异-1.13%[95%CI,-1.84%至-0.42%];HR 0.26[95%CI,0.11-0.64];优效性P=.004)。
关键数值与推荐
- 主要终点相对非劣效界值为50%。
- 主要终点:1个月DAPT组2.36% vs 12个月DAPT组3.70%(绝对差异-1.34%[95%CI,-2.57%至-0.11%];HR 0.64[95%CI,0.42-0.98]),非劣效性P<.001,优效性P=.04。
- 主要次要心血管终点:1个月DAPT组1.96% vs 12个月DAPT组2.51%(绝对差异-0.55%[95%CI,-1.62%至0.52%];HR 0.79[95%CI,0.49-1.29]),非劣效性P=.005,优效性P=.34。
- 主要次要出血终点:1个月DAPT组0.41% vs 12个月DAPT组1.54%(绝对差异-1.13%[95%CI,-1.84%至-0.42%];HR 0.26[95%CI,0.11-0.64];优效性P=.004)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出,鉴于研究局限性,需在其他人群中进行进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Very short mandatory dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with a drug-eluting stent may be an attractive option. OBJECTIVE: To test the hypothesis of noninferiority of 1 month of DAPT compared with standard 12 months of DAPT for a composite end point of cardiovascular and bleeding events. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, open-label, randomized clinical trial enrolling 3045 patients who underwent PCI at 90 hospitals in Japan from December 2015 through December 2017. Final 1-year clinical follow-up was completed in January 2019. INTERVENTIONS: Patients were randomized either to 1 month of DAPT followed by clopidogrel monotherapy (n=1523) or to 12 months of DAPT with aspirin and clopidogrel (n=1522). MAIN OUTCOMES AND MEASURES: The primary end point was a composite of cardiovascular death, myocardial infarction (MI), ischemic or hemorrhagic stroke, definite stent thrombosis, or major or minor bleeding at 12 months, with a relative noninferiority margin of 50%. The major secondary cardiovascular end point was a composite of cardiovascular death, MI, ischemic or hemorrhagic stroke, or definite stent thrombosis and the major secondary bleeding end point was major or minor bleeding. RESULTS: Among 3045 patients randomized, 36 withdrew consent; of 3009 remaining, 2974 (99%) completed the trial. One-month DAPT was both noninferior and superior to 12-month DAPT for the primary end point, occurring in 2.36% with 1-month DAPT and 3.70% with 12-month DAPT (absolute difference, -1.34% [95% CI, -2.57% to -0.11%]; hazard ratio [HR], 0.64 [95% CI, 0.42-0.98]), meeting criteria for noninferiority (P < .001) and for superiority (P = .04). The major secondary cardiovascular end point occurred in 1.96% with 1-month DAPT and 2.51% with 12-month DAPT (absolute difference, -0.55% [95% CI, -1.62% to 0.52%]; HR, 0.79 [95% CI, 0.49-1.29]), meeting criteria for noninferiority (P = .005) but not for superiority (P = .34). The major secondary bleeding end point occurred in 0.41% with 1-month DAPT and 1.54% with 12-month DAPT (absolute difference, -1.13% [95% CI, -1.84% to -0.42%]; HR, 0.26 [95% CI, 0.11-0.64]; P = .004 for superiority). CONCLUSIONS AND RELEVANCE: Among patients undergoing PCI, 1 month of DAPT followed by clopidogrel monotherapy, compared with 12 months of DAPT with aspirin and clopidogrel, resulted in a significantly lower rate of a composite of cardiovascular and bleeding events, meeting criteria for both noninferiority and superiority. These findings suggest that a shorter duration of DAPT may provide benefit, although given study limitations, additional research is needed in other populations. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02619760.
引用
- Watanabe H, Domei T, Morimoto T, et al. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. JAMA. 2019. PMID: 31237644. doi:10.1001/jama.2019.8145
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。